Methotrexate for Central Serous Chorioretinopathy Treatment Trial

NCT01633983 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Central Serous Chorioretinopathy

Interventions

DRUG: Methotrexate
DRUG: Delayed treatment

Sponsor

Edward Averbukh